In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Intercell teams up with GSK for patch-based vaccines

This article was originally published in Clinica

Executive Summary

Austrian biotech firm Intercell is to collaborate with GlaxoSmithKline (GSK) Biologicals on the development and commercialisation of needle-free, patch-based vaccines. The agreement will see the two firms commercialise Intercell’s vaccine patch for travellers’ diarrhoea (TD), which is currently in phase III trials, and work on future pandemic influenza vaccination patch technology. The companies will combine GSK’s patch technology with Intercell’s candidate vaccines. There are presently no vaccines available for TD, said the company. Financial terms of the deal were not disclosed. According to Vienna-based Intercell, the patch technology could provide a new way of delivering vaccines faster, more easily and with fewer doses. Intercell says that each year, around 20 million travellers develop TD while visiting endemic areas such as Asia, Africa and South America.






Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts